BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...Inc. CerRx Inc. Innate Pharma S.A. BioCryst Pharmaceuticals Inc. Johnson & Johnson 4SC AG Medivir AB Bioniz Therapeutics Inc. Codiak BioSciences Inc. Sorrento Therapeutics Inc. Trillium Therapeutics...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB) and Trillium Therapeutics...
...constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium Therapeutics...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB) and Trillium Therapeutics...
...TP53) Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium Therapeutics...
BioCentury | Nov 7, 2020
Management Tracks

Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies

...retire in 1H21, after 27 years with the pharma. The company is searching for her successor.Trillium Therapeutics...
...markets and develops HIV, non-alcoholic steatohepatitis and cancer therapies, hires a successor. Danielle Golovin Eli Lilly and Co. Trillium Therapeutics...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...in Trillium following positive dose-escalation dataPfizer Inc. (NYSE:PFE) made a $25 million equity investment in Trillium Therapeutics...
BioCentury | Mar 2, 2020
Deals

Gilead shows deal appetite, taking out ‘don’t eat me’ play Forty Seven for $4.9B

...“Beefing Up Corp Dev” ). Monday’s deal piqued interest in other companies with CD47 assets. Trillium Therapeutics...
BioCentury | Feb 29, 2020
Deals

Is Forty Seven on Gilead’s ‘urgent’ shopping list?

...Eat That” ). Since then, at least 11 other companies have announced CD47 programs, including Trillium Therapeutics...
...see “Magrolimab Data Lift Forty Seven Shares” ). Elizabeth S. Eaton, Staff Writer Gilead Sciences Inc. Forty Seven Inc. Trillium Therapeutics...
BioCentury | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

...when it proposed the offering after hours. Its stock fell $2.55 (10%) to $23.14 Thursday. Trillium Therapeutics...
...factor receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer Blueprint Medicines Corp. Zymeworks Inc. Zai Lab Ltd. Hutchison China MediTech Ltd. Trillium Therapeutics...
BioCentury | Jan 24, 2020
Financial News

2020 hits ground running with $2.5B in January follow-ons

...when it proposed the offering after hours. The company fell $2.55 (10%) to $23.14 Thursday. Trillium Therapeutics...
...factor receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer Blueprint Medicines Corp. Zymeworks Inc. Zai Lab Ltd. Hutchison China MediTech Ltd. Trillium Therapeutics...
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

...wouldn’t raise money until we’re in the clinic,” said Finer. Robert Kirkman, executive chairman of Trillium Therapeutics...
Items per page:
1 - 10 of 67
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...Inc. CerRx Inc. Innate Pharma S.A. BioCryst Pharmaceuticals Inc. Johnson & Johnson 4SC AG Medivir AB Bioniz Therapeutics Inc. Codiak BioSciences Inc. Sorrento Therapeutics Inc. Trillium Therapeutics...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB) and Trillium Therapeutics...
...constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium Therapeutics...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB) and Trillium Therapeutics...
...TP53) Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium Therapeutics...
BioCentury | Nov 7, 2020
Management Tracks

Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies

...retire in 1H21, after 27 years with the pharma. The company is searching for her successor.Trillium Therapeutics...
...markets and develops HIV, non-alcoholic steatohepatitis and cancer therapies, hires a successor. Danielle Golovin Eli Lilly and Co. Trillium Therapeutics...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...in Trillium following positive dose-escalation dataPfizer Inc. (NYSE:PFE) made a $25 million equity investment in Trillium Therapeutics...
BioCentury | Mar 2, 2020
Deals

Gilead shows deal appetite, taking out ‘don’t eat me’ play Forty Seven for $4.9B

...“Beefing Up Corp Dev” ). Monday’s deal piqued interest in other companies with CD47 assets. Trillium Therapeutics...
BioCentury | Feb 29, 2020
Deals

Is Forty Seven on Gilead’s ‘urgent’ shopping list?

...Eat That” ). Since then, at least 11 other companies have announced CD47 programs, including Trillium Therapeutics...
...see “Magrolimab Data Lift Forty Seven Shares” ). Elizabeth S. Eaton, Staff Writer Gilead Sciences Inc. Forty Seven Inc. Trillium Therapeutics...
BioCentury | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

...when it proposed the offering after hours. Its stock fell $2.55 (10%) to $23.14 Thursday. Trillium Therapeutics...
...factor receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer Blueprint Medicines Corp. Zymeworks Inc. Zai Lab Ltd. Hutchison China MediTech Ltd. Trillium Therapeutics...
BioCentury | Jan 24, 2020
Financial News

2020 hits ground running with $2.5B in January follow-ons

...when it proposed the offering after hours. The company fell $2.55 (10%) to $23.14 Thursday. Trillium Therapeutics...
...factor receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer Blueprint Medicines Corp. Zymeworks Inc. Zai Lab Ltd. Hutchison China MediTech Ltd. Trillium Therapeutics...
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

...wouldn’t raise money until we’re in the clinic,” said Finer. Robert Kirkman, executive chairman of Trillium Therapeutics...
Items per page:
1 - 10 of 67